Gastroenterology

A new study discovers patients with IBD who respond well to high-dose thiamine treatment have an abundance of faecalibacterium prausnitzii.

The HCPLive August gastroenterology month in review spotlights expansions in gastrointestinal treatment and screening access as well as the newest edition of Qazi Corner.

AHN Division of Gastroenterology, Hepatology, and Nutrition addresses patients’ challenging symptoms and needs with wide-ranging strategies and innovative treatments.

Qazi discusses a review of considerations for GLP-1 RA use in the context of endoscopic procedures due to their impact on gastric emptying and bowel motility.

With the growing popularity of GLP-1 receptor agonists, understanding their impact on gastric emptying, bowel motility, and potential implications for endoscopy is essential.

Qazi reviews findings from a study exploring the safety of endoscopic retrograde cholangiopancreatography in the early versus late post-transplant period.

Patients who underwent ERCP ≤ 30 days post-transplant had greater rates of early post-procedure bleeding but similar rates of technical and clinical success compared to late ERCP.

Qazi reviews findings from a study exploring potential causes of seronegative villous atrophy, emphasizing the importance of maintaining a broad differential in diagnosis.

Findings suggest a heterogeneous makeup of seronegative enteropathies, presenting difficulty in diagnosing patients with villous atrophy and negative celiac serologic testing.

The third quarterly issue of 2024 reviews early versus late ERCP outcomes post-transplant, the impact of GLP-1RA use on endoscopic management, and the differential diagnosis of seronegative villous atrophy.

The study was not adequately powered to assess a significant association with cancer mortalities.

Adalimumab-aaty was FDA approved on May 23, 2023, and became commercially available in the US on July 2, 2023.

The July 2024 gastroenterology month in review highlights FDA news, GI pipeline updates, and a new clinical practice update from the American Gastroenterological Assocation.

Grady explains the significance of the recent FDA approval of the first blood-based test for primary CRC screening and his hope for its impact on overall screening rates and compliance.

The phase 2 trial did not meet its primary endpoint for mean change in Crohn’s disease activity index in either VTX958 dosing group.

The approval of Guardant Health’s Shield test makes it the first blood test to be approved as a primary screening option for CRC and the first to meet Medicare coverage requirements.

New research suggests combined treatment with fecal microbiota transplant and anti-PD-1 inhibitors may help overcome immune checkpoint inhibitor resistance in gastrointestinal cancers.

Data from INSPIRE and COMMAND were used to support risankizumab’s FDA approval for ulcerative colitis, demonstrating the IL-23 inhibitor’s impact on clinical remission.

Vonoprazan (Voquezna), the first major innovation in GERD treatment in more than 30 years, is now FDA-approved for both erosive and non-erosive GERD.

Announced on July 18, 2024, the FDA approval for heartburn relief associated with non-erosive GERD is based on the phase 3 PHALCON-NERD-301 trial.

Levinthal explains recent advances in the understanding of CVS and how the AGA clinical practice update reflects new information about its diagnosis and management.

A clinical practice update from the American Gastroenterological Association is providing clinicians with an overview of the diagnosis and management of CVS.

Chehade reviews key findings from the phase 3 EoE kids trial and how they inform dupilumab’s use in children 1-11 years of age with eosinophilic esophagitis.

After a busy first half to 2024, a number of high-impact FDA decisions await the healthcare industry through December.

The June 2024 gastroenterology month in review highlights FDA news and other pipeline developments in GI as well as the publication of the latest installment of Qazi Corner.

A review of the 20 novel drugs approved by the US Food and Drug Administration during the first half of 2024, with links to coverage from MJH Life Sciences publications.

Findings from a post hoc analysis of True North and its open-label extension highlight ozanimod’s rapid onset of action and durability in advanced therapy-naive patients with UC.

Loftus explains the significance of IL-23 and Th17 in IBD and key trial data supporting the FDA approval of risankizumab in ulcerative colitis.

Positive topline results showed guselkumab (Tremfya) SC induction therapy met all primary and secondary endpoints, suggesting similar clinical benefit to IV induction seen in GALAXI.

The approval is based on data from a pair of phase 3 studies and makes risankizumab-rzaa the first IL-23 specific inhibitor approved for both ulcerative colitis and Crohn’s disease.